[1]
|
中华医学会消化病学分会胃肠激素与神经内分泌肿瘤学组. 胃肠胰神经内分泌肿瘤诊治专家共识(2020·广州)[J]. 中华消化杂志, 2021, 41: 76-87. |
[2]
|
Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2013, 40: 800-816. doi: 10.1007/s00259-012-2330-6 |
[3]
|
刘会攀, 陈跃. 放射性核素诊治神经内分泌肿瘤的应用进展[J]. 中华核医学与分子影像杂志, 2019, 39: 564-567. doi: 10.3760/cma.j.issn.2095-2848.2019.09.015 |
[4]
|
Feijtel D, de Jong M, Nonnekens J. Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward[J]. Curr Top Med Chem, 2020, 20: 2959-2969. doi: 10.2174/1568026620666200226104652 |
[5]
|
Ezziddin S, Attassi M, Yong-Hing CJ, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate[J]. J Nucl Med, 2014, 55: 183-190. doi: 10.2967/jnumed.113.125336 |
[6]
|
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. doi: 10.1056/NEJMoa1607427 |
[7]
|
Nicolini S, Severi S, Ianniello A, et al. Investigation of receptor radionuclide therapy with (177)Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index[J]. Eur J Nucl Med Mol Imaging, 2018, 45: 923-930. doi: 10.1007/s00259-017-3925-8 |
[8]
|
Perren A, Couvelard A, Scoazec JY, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification[J]. Neuroendocrinology, 2017, 105: 196-200. doi: 10.1159/000457956 |
[9]
|
Costa F, Gumz B. Octreotide - A Review of its Use in Treating Neuroendocrine Tumours[J]. Eur Endocrinol, 2014, 10: 70-74. |
[10]
|
Calais PJ, Turner JH. Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors[J]. Ann Nucl Med, 2014, 28: 531-539. doi: 10.1007/s12149-014-0843-8 |
[11]
|
王国慧, Lau E, Shakher R, 等. 177Lu-octreotate治疗神经内分泌胃肠胰腺肿瘤的SPECT显像研究[J]. 中华核医学杂志, 2007, 27: 313-314. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHHY200705031.htm |
[12]
|
Erbas B, Tuncel M. Renal Function Assessment During Peptide Receptor Radionuclide Therapy[J]. Semin Nucl Med, 2016, 46: 462-478. doi: 10.1053/j.semnuclmed.2016.04.006 |
[13]
|
Shaheen S, Moradi F, Gamino G, et al. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities[J]. Curr Treat Options Oncol, 2020, 21: 25. doi: 10.1007/s11864-020-0711-9 |
[14]
|
Makis W, McCann K, McEwan AJ. The Challenges of Treating Paraganglioma Patients with 177Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment Protocols[J]. Nucl Med Mol Imaging, 2015, 49: 223-230. doi: 10.1007/s13139-015-0332-6 |
[15]
|
范素云, 柴丽, 贾彦彦, 等. 131I治疗期间甲状腺癌患者未满足的照顾需求分析[J]. 中华核医学与分子影像杂志, 2018, 38: 422-424. |